



असर्फी हॉस्पिटल

सबके लिए स्वास्थ्य

AHL/AO/2025/858

Date: 08.05.2025

To
The BSE Limited
Listing Department
25th Floor, Phiroze Jeejeebhoy Tower,
Dalal Street, Mumbai-400 001

Sub: Outcome of Board Meeting held on 08th May, 2025 and Submission of Standalone & Consolidated audited Financial Results for the quarter ended & year ended 31st March, 2025 as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: - Scrip Code: 543943

Dear Sir/ Ma'am,

Pursuant to the provisions of Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we wish to inform you that the Board of Directors of Asarfi Hospital Limited (the Company), at its meeting held today i.e. on 08th May, 2025 has considered and approved the audited Standalone and Consolidated Financial Results of the Company for the Standalone & Consolidated quarter ended & year ended 31st March, 2025.

A copy of the audited Standalone and Consolidated Financial Results along with the Limited Report issued by the Statutory Auditors, are enclosed herewith. The Board Meeting commenced at 03:00 p.m. and concluded at 8:00 p.m.

You are requested to kindly take the above information on record.

Thanking you,

Yours Faithfully,

For Asarfi Hospital Limited

Udai Pratap Singh
Managing Director

Din: 08453794

Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673
Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || www.asarfihospital.com
Phone: 7808368888, 9234302735 || Email: info@asarfihospital.com

M/S R. K. THAKKAR & CO.

Chartered Accountants

Below 'Central Bank of India', Bank More, Dhanbad, 826001
Mobile: 6203797936; email: rkthakkarco@gmail.com

Independent Auditor's Limited Review Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to,
The Board of Directors,
Asarfi Hospital Limited
Baramuri, Bishunpur Polytechnic,
Dhanbad- 828130 Jharkhand

Dear Sir,

Re: Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of **Asarfi Hospital Limited (the "Company")** for the quarter ended March 31, 2025 and for the year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, ('the Regulation') as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

1. is presented in accordance with the requirements of the Listing Regulations in this regard; and
2. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2025 and for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the



Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Standalone Financial Results

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibility for audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls. • Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit finding, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For R K Thakkar & Co
Chartered Accountants
FRN: 002690C

Place: Dhanbad
Date: 08.05.2025
UDIN: 25415931BMIANT1399



Himanshu Kumar Dokania
(Partner)
Membership No. 415931

Asarfi Hospital Limited

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

Standalone Balance Sheet as at 31 March 2025

(` in Lakhs)

Particulars	As at	
	31-Mar-25	31-Mar-24
	Audited	Audited
I. EQUITY AND LIABILITIES		
(1) Shareholders' funds		
(a) Share Capital	1,967.73	1,967.73
(b) Reserves and Surplus	6,176.00	5,078.03
Total	8,143.73	7,045.76
(2) Non-current liabilities		
(a) Long-term Borrowings	3,382.93	1,744.64
(b) Deferred Tax Liabilities (net)	337.07	271.60
(c) Other Long-term Liabilities	346.34	1,818.54
(d) Long-term Provisions	120.09	97.87
Total	4,186.42	3,932.64
(3) Current liabilities		
(a) Short-term Borrowings	1,472.80	1,446.58
(b) Trade Payables		-
- Due to Micro and Small Enterprises	17.65	38.55
- Due to Others	1,285.68	2,440.77
(c) Other Current Liabilities	765.29	157.82
(d) Short-term Provisions	559.00	345.23
Total	4,100.42	4,428.95
Total Equity and Liabilities	16,430.57	15,407.35
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	10,148.36	9,371.07
(ii) Capital Work-in-progress	193.91	-
(b) Non-current Investments	1.00	1.00
(c) Long term Loans and Advances	86.23	1,319.95
(d) Other Non-current Assets	163.88	165.33
Total	10,593.37	10,857.35
(2) Current assets		
(a) Inventories	227.67	179.99
(b) Trade Receivables	3,979.73	2,425.71
(c) Cash and cash equivalents	131.56	49.10
(d) Short-term Loans and Advances	87.44	303.71
(e) Other Current Assets	1,410.81	1,591.49
Total	5,837.20	4,550.00
Total Assets	16,430.57	15,407.35

Place: Dhanbad

For Asarfi Hospital Limited

Uday Pratap Singh
Managing Director
DIN: 08453794
08453794

For Asarfi Hospital Limited

Madhuri Singh
Director
DIN: 08562038

For and on behalf of the Board of
Asarfi Hospital Limited

(Harendra Singh)
Chief Financial Officer
PAN: BANPS9243R
BANPS9243R



Statement of Audited Standalone Financial Results for the Quarter & Year ended 31 March 2025

(` in Lakhs)

Particulars	Quarter ended				Half Yearly			Year Ended	
	31-Mar-25	31-Mar-24	31-Dec-24	31-Dec-23	31-Mar-25	30-Sep-24	30-Sep-23	31-Mar-25	31-Mar-2024
	Refer Note 7	Refer Note 7	Unaudited	Unaudited	Refer Note 7	Unaudited	Unaudited	Audited	Audited
Revenue from Operations	3,389.20	2,403.76	3,289.01	2,004.57	6,678.21	5,378.36	4,031.70	12,056.57	8,440.04
Other Income	486.88	(41.13)	89.47	120.21	576.34	180.55	87.93	756.90	167.01
Total Income	3,876.08	2,362.64	3,378.48	2,124.78	7,254.56	5,558.92	4,119.63	12,813.47	8,607.05
Expenses									
Cost of Material Consumed	504.11	433.97	488.70	433.97	992.81	947.17	753.00	1,939.98	1,620.94
Purchases of Stock in Trade	247.93	135.50	257.84	92.19	505.76	403.54	203.22	909.31	430.90
Change in Inventories of work in progress and finished goods	(2.53)	14.87	(28.43)	(32.46)	(30.97)	(32.40)	(2.18)	(63.37)	(19.77)
Employee Benefit Expenses	590.01	414.75	452.33	351.32	1,042.33	818.69	647.06	1,861.02	1,413.13
Finance Costs	134.75	76.37	117.50	59.98	252.25	155.84	132.88	408.09	269.23
Depreciation and Amortization Expenses	323.02	348.78	303.63	324.64	626.66	635.08	439.67	1,261.74	878.25
Other Expenses	1,525.28	1,005.15	1,421.02	759.29	2,946.29	2,078.95	1,620.74	5,025.24	3,385.19
Total expenses	3,322.57	2,429.39	3,012.58	1,988.91	6,335.14	5,006.87	3,794.40	11,342.01	7,977.87
Profit/(Loss) before Exceptional and Extraordinary Item and Tax	553.51	(66.75)	365.90	135.86	919.41	552.05	325.23	1,471.46	629.18
Exceptional Item			-	-					
Profit/(Loss) before Extraordinary Item and Tax	553.51	(66.75)	365.90	135.86	919.41	552.05	325.23	1,471.46	629.18
Extraordinary Item			-	-					
Profit/(Loss) before Tax	553.51	(66.75)	365.90	135.86	919.41	552.05	325.23	1,471.46	629.18
Tax Expenses									
- Current Tax	144.08	-	163.48	-	307.56	-	-	307.56	-
- Deferred Tax	26.57	(37.77)	(69.52)	109.95	(42.95)	108.42	118.38	65.46	190.56
-Prior Period Taxes	-	(13.04)	-	30.44	-	0.46	-	0.46	17.40
Profit/(Loss) after Tax	382.86	(15.94)	271.94	(4.52)	654.80	443.17	206.85	1,097.97	421.22
Profit/(Loss) for the period (before Minority interest adjustment)	382.86	(15.94)	271.94	(4.52)	654.80	443.17	206.85	1,097.97	421.22
Less: Minority interest in (Profit)/losses									
Profit/(Loss) for the period (after Minority interest adjustment)	382.86	(15.94)	271.94	(4.52)	654.80	443.17	206.85	1,097.97	421.22
Earnings Per Share (Face Value per Share Rs.10 each)									
-Basic (In Rs)	1.95	-0.16	1.38	(0.02)	3.33	2.25	1.73	5.58	2.33
-Diluted (In Rs)	1.95	-0.16	1.38	(0.02)	3.33	2.25	1.73	5.58	2.33

1 The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on May 08, 2025.

2 The Statutory Auditor of the company carried out the limited Review of above result as per Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 As per Accounting Standard - 17 on "Segment Reporting" (AS 17), the company has only one reportable segment viz Hospital.

4 As per MCA notification dated 16th February 2015 companies whose shares are listed in SME exchange as referred to Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018 are exempted from compulsory requirement of adoption of IND AS.

5 Earning per Share are calculated on weighted average of the share capital outstanding during the year/ Quarter / period EPS is not annualised.

6 Previous year/s/ period's have been regrouped/ rearranged wherever necessary.

7 The figures for the quarter ended March 31, 2025 & March 31, 2024 and half year ended March 31, 2025 is the balancing figures between audited figures in respect of full financial year and published year to date reviewed figures up to third quarter of the year ended March 31, 2025 & March 31, 2024 and half year ended September 30, 2024 respectively.

For Asarfi Hospital Limited

For Asarfi Hospital Limited

For and on behalf of the Board

Asarfi Hospital Limited

Place: Dhanbad
Date: 08.05.2025



Uday Pratap Singh
Managing Director
DIN-08453794

Madhuri Singh
Director
DIN-06562038

(Harendra Singh)
Chief Financial Officer
PAN: BANPS9243R

Asarfi Hospital Limited

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

Stand alone Cash Flow Statement for the year ended 31 March 2025

(` in 'Lakhs)

Particulars	For the	
	Year Ended	Year Ended
	31-Mar-2025	31-Mar-2024
	Audited	Audited
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit after tax	1,097.97	421.22
Profit/(loss) from Discontinuing Operation (after tax)	-	-
Depreciation and Amortisation Expense	1,261.74	878.25
Provision for tax	373.49	207.96
Loss/(Gain) on Sale / Discard of Assets (Net)	(39.80)	-
Non operating Income	(323.82)	-
Non operating Expenses	30.99	-
Interest Income	(125.68)	(70.29)
Finance Costs	408.09	269.23
Operating Profit before working capital changes	2,682.98	1,706.36
Adjustment for:		
Inventories	(47.68)	(37.52)
Trade Receivables	(1,554.02)	(732.64)
Loans and Advances	256.55	135.36
Other Current Assets	(8.27)	(5.81)
Trade Payables	(1,193.69)	1,980.50
Other Current Liabilities	(106.38)	(384.85)
Long term Liabilities	(340.74)	-
Short-term Provisions	212.79	(78.85)
Long-term Provisions	22.22	26.68
Cash (Used in)/Generated from Operations	(76.23)	2,609.25
Tax paid(Net)	308.03	17.40
Net Cash (Used in)/Generated from Operating Activities	(384.26)	2,591.85
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment & CWIP	(968.85)	(4,601.33)
Decrease /Increase in Capital WIP	(193.91)	-
Purchase of Equity Instruments	-	(1.00)
Sale of Property, Plant and Equipment	129.15	-
Loan & Advances Given	(72.64)	(764.43)
Investment in Term Deposits	-	(968.53)
Maturity of Term Deposits	183.32	-
Movement in other non current assets	7.09	(48.85)
Interest received	125.68	70.29
Dividend received	-	-
Net Cash (Used in)/Generated from Investing Activities	(790.16)	(6,313.86)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Share Capital	-	2,310.27
Buyback of Shares	-	-
Proceeds from Long Term Borrowings	2,203.80	1,167.56
Repayment of Long Term Borrowings	(467.73)	(214.18)
Proceeds from Short Term Borrowings	13.27	517.64
Repayment of Short Term Borrowings	(84.83)	-
Adjustment in Reserve & Surplus	-	128.62
Dividends Paid (including Dividend Distribution Tax)	-	-
Interest Paid	(407.63)	(269.23)
Net Cash (Used in)/Generated from Financing Activities	1,256.88	3,640.68
Net Increase/(Decrease) in Cash and Cash Equivalents	82.46	(81.33)
Opening Balance of Cash and Cash Equivalents	49.10	130.42
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
Closing Balance of Cash and Cash Equivalents	131.56	49.10

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

For and on behalf of the Board of
Asarfi Hospital Limited

For Asarfi Hospital Limited
Place: Dhanbad
Date: 08.05.2025
Uday Pratap Singh
(Uday Pratap Singh)
DIN-08453794

For Asarfi Hospital Limited
Madhuri Singh
Director
(Madhuri Singh)
DIN-06562038

(Harendra Singh)
Chief Financial Officer
PAN: BANPS9243R



M/S R. K. THAKKAR & CO.

Chartered Accountants

Below 'Central Bank of India', Bank More, Dhanbad, 826001
Mobile: 6203797936; email: rkthakkarco@gmail.com

Independent Auditor's Limited Review Report on the Quarterly and Year to Date Audited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to,
The Board of Directors,
Asarfi Hospital Limited
Baramuri, Bishunpur Polytechnic,
Dhanbad- 828130 Jharkhand

Dear Sir,

Re: Report on the audit of the Consolidated Financial Results

Opinion


We have audited the accompanying statement of quarterly and year to date consolidated financial results of **ASARFI HOSPITAL LIMITED (the "Company")**, which include its subsidiary namely *Asarfi Educational Foundation*, for the quarter ended 31st March, 2025 and the year ended 31st March 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, ('the Regulation') as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

1. is presented in accordance with the requirements of the Listing Regulations in this regard; and
2. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2025 and for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical



requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Consolidated Financial Results

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.


In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibility for audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls. • Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit finding, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For R K Thakkar & Co
Chartered Accountants
FRN: 002690C

Place: Dhanbad
Date: 08.05.2025
UDIN: 25415931BMIANU7835


Himanshu Kumar Dokania
(Partner)
Membership No. 415931



Asarfi Hospital Limited

(CIN: L85110JH2005PLC011673)

(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)

Consolidated Balance Sheet as at 31 March 2025

(` in Lakhs)

Particulars	As at	
	31-Mar-25	31-Mar-24
	Audited	Audited
I. EQUITY AND LIABILITIES		
(1) Shareholders' funds		
(a) Share Capital	1,967.73	1,967.73
(b) Reserves and Surplus	6,130.59	5,072.97
Total	8,098.32	7,040.70
(2) Non-current liabilities		
(a) Long-term Borrowings	3,382.93	1,744.64
(b) Deferred Tax Liabilities (net)	337.07	271.60
(c) Other Long-term Liabilities	346.34	1,818.54
(d) Long-term Provisions	120.09	97.87
Total	4,186.42	3,932.64
(3) Current liabilities		
(a) Short-term Borrowings	1,472.80	1,446.58
(b) Trade Payables		-
- Due to Micro and Small Enterprises	17.65	44.61
- Due to Others	1,285.92	2,441.13
(c) Other Current Liabilities	767.19	157.82
(d) Short-term Provisions	560.36	345.33
Total	4,103.92	4,435.47
Total Equity and Liabilities	16,388.67	15,408.82
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	10,164.44	9,376.64
(ii) Capital Work-in-progress	193.91	-
(b) Non-current Investments	18.00	-
(c) Long term Loans and Advances	-	1,306.36
(d) Other Non-current Assets	163.88	165.33
Total	10,540.23	10,848.33
(2) Current assets		
(a) Inventories	227.67	179.99
(b) Trade Receivables	3,979.73	2,425.71
(c) Cash and cash equivalents	142.63	59.12
(d) Short-term Loans and Advances	87.61	304.18
(e) Other Current Assets	1,410.81	1,591.49
Total	5,848.44	4,560.49
Total Assets	16,388.67	15,408.82

Place: Dhanbad

Date: 08.05.2025

For Asarfi Hospital Limited

Udai Pratap Singh
 Director
 PAN: BANPS9243R
 DIN-08453794

For Asarfi Hospital Limited

माधुरी सिंह
 Director
 PAN: BANPS9243R
 DIN-06562038

**For and on behalf of the Board of
 Asarfi Hospital Limited**

Harendra Singh
 Chief Financial Officer
 PAN: BANPS9243R



Asarfi Hospital Limited
(CIN: L85110JH2005PLC011673)
(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)
Statement of Audited Consolidated Financial Results for the Quarter & Year ended 31 March 2025

(in Lakhs)

Particulars	Quarter ended			Half Yearly		Year Ended	
	31-Mar-25	31-Mar-24	31-Dec-24	31-Mar-25	30-Sep-24	31-Mar-25	31-Mar-2024
	Refer Note 7	Refer Note 7	Unaudited	Refer Note 7	Unaudited	Audited	Audited
Revenue from Operations	3,389.20	2,403.76	3,289.01	6,678.21	5,378.36	12,056.57	8,440.04
Other Income	481.97	(41.13)	89.47	571.44	180.55	751.99	167.01
Total Income	3,871.17	2,362.64	3,378.48	7,249.65	5,558.92	12,808.56	8,607.05
Expenses							
Cost of Material Consumed	504.11	433.97	488.70	992.81	947.17	1,939.98	1,620.94
Purchases of Stock in Trade	247.93	135.50	257.84	505.76	403.54	909.31	430.90
Change in Inventories of work in progress and finished goods	(2.53)	14.87	(28.43)	(30.97)	(32.40)	(63.37)	(19.77)
Employee Benefit Expenses	591.79	414.75	452.75	1,044.54	818.69	1,863.23	1,413.13
Finance Costs	134.75	76.37	117.50	252.25	155.84	408.09	269.23
Depreciation and Amortization Expenses	325.03	349.28	304.90	629.93	637.67	1,267.60	878.75
Other Expenses	1,540.58	1,009.72	1,422.78	2,963.36	2,089.26	5,052.61	3,389.75
Total expenses	3,341.66	2,434.46	3,016.03	6,357.70	5,019.76	11,377.45	7,982.93
Profit/(Loss) before Exceptional and Extraordinary Item and Tax	529.51	(71.82)	362.44	891.95	539.16	1,431.11	624.12
Exceptional Item							
Profit/(Loss) before Extraordinary Item and Tax	529.51	(71.82)	362.44	891.95	539.16	1,431.11	624.12
Extraordinary Item	-						
Profit/(Loss) before Tax	529.51	(71.82)	362.44	891.95	539.16	1,431.11	624.12
Tax Expenses							
- Current Tax	144.08	-	163.48	307.56	-	307.56	-
- Deferred Tax	26.57	(37.77)	(69.52)	(42.95)	108.42	65.46	190.56
-Prior Period Taxes	-	(13.04)	-	-	0.46	0.46	17.40
Profit/(Loss) after Tax	358.86	(21.01)	268.49	627.35	430.28	1,057.62	416.16
Profit/(Loss) for the period (before Minority interest adjustment)	358.86	(21.01)	268.49	627.35	430.28	1,057.62	416.16
Less: Minority interest in (Profit)/losses							
Profit/(Loss) for the period (after Minority interest adjustment)	358.86	(21.01)	268.49	627.35	430.28	1,057.62	416.16
Earnings Per Share (Face Value per Share Rs.10 each)							
-Basic (In Rs)	1.82	-0.18	1.36	3.19	2.19	5.37	2.31
-Diluted (In Rs)	1.82	-0.18	1.36	3.19	2.19	5.37	2.31

- The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on May 08, 2025.
- The Statutory Auditor of the company carried out the limited Review of above result as per Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- As per Accounting Standard - 17 on "Segment Reporting" (AS 17), the company has only one reportable segment viz Hospital.
As per MCA notification dated 16th February 2015 companies whose shares are listed in SME exchange as referred to Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018 are exempted from compulsory requirement of adoption of IND AS.
- Earning per Share are calculated on weighted average of the share capital outstanding during the year/ Quarter / period EPS is not annualised.
- Previous year's/ period's have been regrouped/ rearranged wherever necessary.
- The figures for the quarter ended March 31, 2025 & March 31, 2024 and half year ended March 31, 2025 is the balancing figures between audited figures in respect of full financial year and published year to date reviewed figures up to third quarter of the year ended March 31,2025 & March 31, 2024 and half year ended September 30, 2024 respectively.

Place: Dhanbad
Date: 08.05.2025



For Asarfi Hospital Limited

(Signature)
Uday Pratap Singh
Managing Director
DIN-08453794

For Asarfi Hospital Limited

(Signature)
Madhuri Singh
Director
DIN-06562038

For and on behalf of the Board
Asarfi Hospital Limited

(Signature)
Harendra Singh
Chief Financial Officer
PAN: BANPS9243R

Asarfi Hospital Limited
(CIN: L85110JH2005PLC011673)
(Address: Baramuri, Bishunpur Polytechnic, Dhanbad)
Consolidated Cash Flow Statement for the year ended 31 March 2025

(' in 'Lakhs)

Particulars	For the	
	Year Ended	Year Ended
	31-Mar-2025	31-Mar-2024
	Audited	Audited
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit after tax	1,057.62	416.16
Profit/(loss) from Discontinuing Operation (after tax)	-	-
Depreciation and Amortisation Expense	1,267.60	878.75
Provision for tax	373.49	207.96
Loss/(Gain) on Sale / Discard of Assets (Net)	(39.80)	-
Non operating Income	(323.82)	-
Non operating Expenses	30.99	-
Interest Income	(120.77)	(70.29)
Finance Costs	408.09	269.23
Operating Profit before working capital changes	2,653.40	1,701.81
Adjustment for:		
Inventories	(47.68)	(37.52)
Trade Receivables	(1,554.02)	(732.64)
Loans and Advances	256.42	148.95
Other Current Assets	(8.27)	(5.81)
Other Non current Assets	(18.00)	-
Trade Payables	(1,199.87)	1,986.92
Other Current Liabilities	(104.48)	(384.85)
Long term Liabilities	(340.74)	-
Short-term Provisions	214.05	(52.07)
Long-term Provisions	22.22	-
Cash (Used in)/Generated from Operations	(126.95)	2,624.80
Tax paid(Net)	308.03	17.40
Net Cash (Used in)/Generated from Operating Activities	(434.98)	2,607.41
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment & CWIP	(984.81)	(4,607.39)
Sale of Property, Plant and Equipment	129.15	-
Purchase of Investments Property	-	-
Decrease /Increase in Capital WIP	(193.91)	-
Purchase of Equity Instruments	-	-
Sale of Property, Plant and Equipment	-	-
Loan & Advances Given	-	(764.90)
Investment in Term Deposits	-	(968.53)
Maturity of Term Deposits	183.32	-
Movement in other non current assets	7.09	(48.85)
Interest received	120.77	70.29
Dividend received	-	-
Net Cash (Used in)/Generated from Investing Activities	(738.39)	(6,319.38)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Share Capital	-	2,310.27
Buyback of Shares	-	-
Proceeds from Long Term Borrowings	2,203.80	1,167.56
Repayment of Long Term Borrowings	(467.73)	(214.18)
Proceeds from Short Term Borrowings	13.27	517.64
Repayment of Short Term Borrowings	(84.83)	-
Adjustment in Reserve & Surplus	-	128.62
Dividends Paid (including Dividend Distribution Tax)	-	-
Interest Paid	(407.63)	(269.23)
Net Cash (Used in)/Generated from Financing Activities	1,256.88	3,640.68
Net Increase/(Decrease) in Cash and Cash Equivalents	83.51	(71.30)
Opening Balance of Cash and Cash Equivalents	59.12	130.42
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
Closing Balance of Cash and Cash Equivalents	142.63	59.12

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

For and on behalf of the Board of
Asarfi Hospital Limited

For Asarfi Hospital Limited

Dhanbad
Date: 08.05.2025

Udai Pratap Singh
(Udai Pratap Singh)
DIN-08453794

For Asarfi Hospital Limited

Madhuri Singh
Director
6562038
(Madhuri Singh)
DIN-06562038

(Harendra Singh)
Chief Financial Officer
PAN: BANPS9243R

